Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Marseille Cedex 5, France Clinical Trials

A listing of Marseille Cedex 5, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (14) clinical trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Acute and late side effects of TBI in combination with other chemotherapeutic are manifold to the growing organism and include severe organ dysfunction/failure due to toxicity. Although transplant associated mortality was reduced after HSCT in the last decade due to better HLA matching, infection prevention and control, the burden of ...

Phase

0.0 miles

Learn More »

An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

The Ependymoma Program is a comprehensive program to improve the accuracy of the primary diagnosis of ependymoma and explore different therapeutic strategies in children, adolescents and young adults, accordingly. This program is opened to all patients diagnosed with ependymoma below the age of 22 years. It will include a centralised ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours

At the same time as these results, triple therapies involving 5FU + oxiplatin + irinotecan have objectively shown a significant increase in overall survival of patients with metastatic pancreatic adenocarcinoma compared to gemcitabine alone (median of 11.1 months versus 6.8 months, HR = 0.57 [0.45 - 0.73] p < 0.0001). ...

Phase

0.0 miles

Learn More »

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Background : Multiple system atrophy (MSA) is a rare, sporadic progressive neurodegenerative disorder, rapidly leading to severe disability and impairment of quality of life. MSA is characterized by a variable combination of a poor levodopa parkinsonism and /or cerebellar ataxia and autonomic failure (cardiovascular and / or bladder and sexual ...

Phase

0.0 miles

Learn More »

Effects of PR Oxycodone and of Levodopa vs Placebo on Central Neuropathic Pain in Parkinson's Disease

The treatment period (11 weeks) will be divided into three periods: A titration phase of two weeks, during which of the doses of the treatments will be gradually increased in three steps: Level 1 (from D1 to D5): Oxycodone: 10 mg PR/day bid (5 mg PR/5 mg PR) Levodopa: 100 ...

Phase

0.0 miles

Learn More »

Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day and 16 mg/day in the treatment of subjects with early Alzheimer's Disease compared to placebo.

Phase

0.0 miles

Learn More »

An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will compare the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, phase 2 study that, on the basis ...

Phase

0.0 miles

Learn More »

Selinexor in Advanced Liposarcoma

In the Phase 2 portion of the study, 57 patients were randomized to selinexor (60 mg) or placebo at a 1:1 allocation ratio. In the Phase 3 portion of the study, approximately 222 patients will be randomized to selinexor (60 mg) or placebo with a 2:1 allocation ratio. Patients who ...

Phase

0.0 miles

Learn More »

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

Subjects participating in this study will be followed from time of roll-over from the parent GM T protocol until 15 years after the last GMT infusion, withdrawal of consent, lost to follow-up, or death, whichever occurs first. Both local and central laboratory evaluations and safety assessments will be conducted during ...

Phase

0.0 miles

Learn More »

Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

Colonic microbiota changes may play a key role in the pathogenesis of acute diverticulitis. A previous proof-of-concept study suggests that rifaximin, a low-absorbable oral antibiotic, may be beneficial for prevention of acute diverticulitis recurrence by modulating the gut microflora. The main objective of this study is to evaluate the safety ...

Phase

0.0 miles

Learn More »